CJC-1295 with DAC: Extended GHRH Analog Research
This comprehensive guide examines the latest research on cjc-1295 dac research, covering mechanisms of action, published study data, research protocols, and safety considerations. As the field of peptide science continues to advance, understanding the evidence base for specific compounds and applications becomes increasingly important for researchers and investigators.
CJC-1295 DAC research has established this modified growth hormone releasing hormone analog as one of the most potent sustained-release GH secretagogues available for investigation. The Drug Affinity Complex (DAC) modification represents an innovative pharmaceutical approach to extending peptide half-life through albumin binding, transforming a short-acting GHRH analog into a long-duration GH-elevating compound.
Researchers can access high-purity research compounds through Proxiva Labs, with all products verified via our third-party testing program.
Drug Affinity Complex (DAC) Technology
The DAC modification attached to CJC-1295 consists of a reactive chemical group (maleimidopropionic acid linked to a lysine linker) that forms a covalent bond with serum albumin after injection. This albumin conjugation dramatically extends the peptide’s circulating half-life.
- Albumin binding — Within minutes of subcutaneous injection, the DAC moiety reacts with circulating albumin, creating a long-lived peptide-protein conjugate
- Half-life extension — Native GHRH has a half-life of approximately 7 minutes. CJC-1295 without DAC extends this to approximately 30 minutes. CJC-1295 with DAC extends it to approximately 6-8 days
- Sustained GH elevation — The extended half-life produces continuous GHRH receptor stimulation, maintaining elevated GH and IGF-1 levels for days after a single injection
- Reduced injection frequency — The long half-life allows weekly or twice-weekly dosing, compared to the multiple daily injections required for unmodified GHRH analogs
Pharmacokinetics and GH Pulsatility
The sustained GHRH receptor stimulation from CJC-1295 DAC creates a distinct pharmacokinetic profile with important implications for GH physiology.
- IGF-1 elevation — Clinical studies showed dose-dependent IGF-1 elevation persisting for 6-14 days after a single injection, with 2-3x baseline levels achievable at higher doses
- GH pulse amplification — Rather than creating a single large GH spike, CJC-1295 DAC amplifies the natural pulsatile GH release pattern, increasing both pulse amplitude and GH trough levels
- Pulsatility concerns — Some researchers note that continuous GHRH stimulation may blunt the natural GH pulsatility over time, potentially leading to partial receptor desensitization
- Accumulation — With repeated weekly dosing, some degree of IGF-1 accumulation occurs before reaching steady-state levels, typically by the 2nd-3rd week of treatment
Clinical Research Data
CJC-1295 DAC has undergone clinical investigation with published pharmacokinetic and pharmacodynamic data.
Phase 1/2 Clinical Findings
Clinical trials demonstrated that single subcutaneous doses of CJC-1295 DAC produced dose-dependent increases in GH and IGF-1 levels. The 30 mcg/kg dose produced peak IGF-1 levels approximately 2x baseline at day 2-3 post-injection, maintaining elevation above baseline for 6-14 days. Multiple dosing at weekly intervals showed sustained IGF-1 elevation without evidence of tolerance over the study duration.
- 30-60 mcg/kg subcutaneous doses were most commonly studied
- Peak GH response occurred 1-4 hours post-injection
- IGF-1 elevation persisted for 6-14 days after single dose
- Weekly dosing maintained steady-state IGF-1 elevation
DAC vs No-DAC: Key Differences
Understanding the differences between CJC-1295 with DAC and without DAC (also known as modified GRF 1-29 or Mod GRF) is critical for research design.
- Half-life — DAC: 6-8 days vs No-DAC: approximately 30 minutes
- Dosing frequency — DAC: 1-2x weekly vs No-DAC: 2-3x daily
- GH pattern — DAC: sustained elevation with amplified pulses vs No-DAC: discrete GH pulses following each injection
- IGF-1 profile — DAC: persistently elevated vs No-DAC: transient spikes following doses
- Pulsatility preservation — No-DAC may better preserve natural GH pulsatility due to intermittent rather than continuous receptor stimulation
- Combination use — No-DAC is commonly combined with GHRPs like ipamorelin; DAC is typically used as a standalone due to its sustained activity
Research Protocols and Dosing
Published research provides clear dosing parameters for CJC-1295 DAC investigation.
- Standard research dose — 2 mg (approximately 30 mcg/kg for a 70 kg subject) subcutaneous injection
- Frequency — Once or twice weekly in most protocols
- Duration — 4-12 week study periods most common
- Monitoring — IGF-1, GH (multiple time-point sampling), glucose, insulin, and body composition measurements
- Storage — Reconstituted CJC-1295 DAC should be refrigerated and used within 3-4 weeks
Key References
- Ghigo et al., 1998 — GH secretagogues
- Bowers et al., 1999 — GHRP research
- Ionescu & Bhatt, 2010 — tesamorelin
Related Research Resources
Explore related topics in our research guide library:
- Peptides For Wound Healing
- Bpc 157 Gut Healing Research
- Peptides For Libido Research
- Peptides For Brain Fog Research
- Browse All Research Guides
Conclusion
CJC-1295 DAC represents an important advance in GH secretagogue pharmacology, demonstrating how bioconjugation technology can transform peptide pharmacokinetics. Its extended half-life, sustained GH/IGF-1 elevation, and reduced injection frequency make it a valuable research tool for investigating the effects of chronic GHRH stimulation on body composition, metabolism, and age-related GH decline.
Researchers can explore our full catalog of research peptides and access the latest peptide research guides for ongoing updates in this rapidly evolving field.